|
|
Post by awesomo on May 12, 2021 18:08:15 GMT -5
21% increase in selling, general and administrative costs to $17.4M, driven by additional headcount for the Afrezza commercial team
1% increase in Afrezza net revenue over Q1 2020
Biggest commercial plan is to sponsor a car...again.
And Mike and company got a 95% score on their Afrezza performance regarding bonuses. What a joke.
|
|
|
|
Post by cretin11 on May 12, 2021 18:15:27 GMT -5
21% increase in selling, general and administrative costs to $17.4M, driven by additional headcount for the Afrezza commercial team 1% increase in Afrezza net revenue over Q1 2020 Biggest commercial plan is to sponsor a car...again. And Mike and company got a 95% score on their Afrezza performance regarding bonuses. What a joke. I guess it’s nice when you get to design your own performance grading system... |
|
|
|
Post by bones1026 on May 12, 2021 21:40:09 GMT -5
Well that answers what a big chunk of the 230 million is used for. Hopefully someone at the shareholders meeting will ask what their plans are for the rest of it. I would question the ad choice, but I don’t think it cost them “a big chunk” of 230M? 230 is a huge chunk of cash to have right now..you can take a few small gambles that could possibly payoff immensely |
|
|
|
Post by mymann on May 12, 2021 22:40:43 GMT -5
Sticker up a clown car in a circus would be this clown's move as a clown ceo.
|
|
|
|
Post by hellodolly on May 13, 2021 5:49:54 GMT -5
Here is what it takes to be a sponsor in the two largest racing series www.hagerty.com/media/hagerty-magazine/how-to-sponsor-two-largest-racing-series/"It was a single-race deal that later expanded into a second weekend, and it was a novel experience. Dipping my financial toes into the most affordable tier of professional racing sponsorship got me thinking: What would it have cost to place the same-size sticker advertising my podcast—the Unnamed Automotive Podcast—on a car in a series with a much higher profile? The answer wasn’t exactly easy to pin down, but it was a whole lot more than the $250 I’d paid. “I’d say $125,000 to $200,000 for the season, depending on how competitive the car and team are,” says a longtime sponsor representative in NASCAR. “The problem is that some categories of product bring more money than others, and if that product is used in the car or by the team and driver, it greatly affects the cost-value equation. It’s hard to generalize, because sponsorship today is much more than a decal.” In fact, in modern racing, sponsors are often just as happy to provide hospitality and then brand that aspect of a race weekend as they would be to secure a spot on the car itself. Dale Coyne, principal at IndyCar’s Dale Coyne Racing, agrees there’s no hard-and-fast answer. “It depends on your underlying sponsorship,” he says. If your primary sponsor wants a clean car, there might not be room for a small sticker. But there’s usually plenty of real estate.” In IndyCar, Coyne says a $20,000 sticker would be small and likely placed behind the front wheel, a spot not all that visible. “For $250,000, now you’re talking the end of the front wing. Sometimes, you’ll have a local company come in for a single race, and for $50,000, it’ll snag a spot that might otherwise have cost a quarter million for the entire year.” Regardless of the series or the teams running in them, visibility of the sponsor’s logo and the relationship between a sponsor and team are vital. From YouTube and more likely a few million: www.youtube.com/watch?v=eif1eP_LQoU |
|
|
|
Post by sweedee79 on May 13, 2021 6:25:42 GMT -5
We need to be proving superiority or finding some other way to market Afrezza..
As it is most docs don't know how to dose Afrezza.. or they don't want to prescribe.. leads to patients having a bad experience.. won't create new customers.. I have experienced this first hand and Mike has not done much to change this problem in all of the years he has been CEO.
The real cost of this is more unhappy customers that don't stay on Afrezza.. We are spinning our wheels doing more of the same .. it didn't work in the past and won't work now.. And how many people are actually going to see a small sticker on a car? I'm disappointed..
Address the actual problems rather than throwing more money at something that isn't working in the first place..
|
|
|
|
Post by rickf on May 13, 2021 6:55:56 GMT -5
We need to be proving superiority or finding some other way to market Afrezza.. As it is most docs don't know how to dose Afrezza.. or they don't want to prescribe.. leads to patients having a bad experience.. won't create new customers.. I have experienced this first hand and Mike has not done much to change this problem in all of the years he has been CEO. The real cost of this is more unhappy customers that don't stay on Afrezza.. We are spinning our wheels doing more of the same .. it didn't work in the past and won't work now.. And how many people are actually going to see a small sticker on a car? I'm disappointed.. Address the actual problems rather than throwing more money at something that isn't working in the first place.. I TOTALLY agree --- the way it is going - I will be dead by the time this company actually does move forward in a meaningful way! IF it ever does!!! My thoughts - Our BEST hope might be that Marine Rothblatt (or someone like her) buys the company and THEN i do believe we would see Afrezza pushed towards success!!! I am soooooooo tired of the way this company has been managed - Dr. Mann is likely rolling in his grave!Y up - I'm pissed!! |
|
|
|
Post by barnstormer on May 13, 2021 7:31:56 GMT -5
I haven't posted here for a while because as my mother used to say "If you can't say something nice, don't say anything" and so since I went from an enthusiastic investor in MNKD to a disillusioned cynic I have tried to follow that advice. This board has always been the best source of intelligent posts and knowledge and still is and with respect I will proceed. After yesterday's earnings call it has become impossible to be silent when it is quite apparent that my worst fears about the current CEO is well founded. Mike has been the artful dodger regarding the erosion of Afrezza scrips and it's time to cease his term as CEO. He was hired not to be a CEO, but to make Afrezza a success. What ever happened to the phrase "standard of care"? He collects a salary that is above his competence level and bonuses he doesn't deserve. You could hear the skepticism in the analysts voices as they asked their usual questions. Mike has talked about partners he has been negotiating with since he became CEO, but the only one we have is UTHR and he can't claim that one as his own. He has said he has been negotiating with Canada and Mexico for years with nothing to show. BIOM & CIPLA are disasters. He spent $12 million on a barn based (you can't make that up) Qrum company with no revenue, no FDA approved drugs and who knows how much more cash it will take to develop. He has been desperate to create the illusion of a pipeline (including RLS) that is years away from generating cash if they are successful. So IMHO it's time to end the Castagna experiment, time for Kresa to give up his seat on the BOD, for the ever expensive Tross to clear out his desk and bring in some fresh eyes or we will continue to be disappointed at all future earnings calls.
|
|
|
|
Post by Clement on May 13, 2021 7:46:35 GMT -5
I just placed an order to buy more MNKD.
|
|
|
|
Post by uvula on May 13, 2021 7:56:03 GMT -5
I mostly agree with barnstormer, but I don't think mnkd can make afrezza successful even with a new ceo.
My wish: uthr buys mnkd and sells off afrezza to a large company who can fund a large clinical study to prove superiority and get the standard of care updated.
It is probably more likely that I win the lottery. And I never buy lottery tickets.
|
|
|
|
Post by Clement on May 13, 2021 7:58:20 GMT -5
MNKD is going to triple in 2 years due to Tyvaso DPI. I am long.
|
|
|
|
Post by barnstormer on May 13, 2021 8:32:49 GMT -5
That's what everyone thought about Afrezza. The stock would fly. Then reality set in and inhalable insulin didn't take off. Even Martine stated on an investor's call that there was no guarantee PAH patients would convert to Tyvaso. So I hope (not a good investment strategy) you're right and the stock triples. But that's what we hoped for with Afrezza.
|
|
|
|
Post by peppy on May 13, 2021 8:38:51 GMT -5
That's what everyone thought about Afrezza. The stock would fly. Then reality set in and inhalable insulin didn't take off. Even Martine stated on an investor's call that there was no guarantee PAH patients would convert to Tyvaso. So I hope (not a good investment strategy) you're right and the stock triples. But that's what we hoped for with Afrezza. Hello Barnstormer, I read every word you have written and consider them. Consider the promise of COPD. COPD with Martine leading the charge. Perhaps that is what is being priced in. As far as partners, I am hoping CEO's look at what Martine is doing and wonder why she is having all the fun. Just talkin. |
|
|
|
Post by mcbone on May 13, 2021 8:43:32 GMT -5
MNKD is going to triple in 2 years due to Tyvaso DPI. I am long. I think you are correct, Clement. MNKD is holding what is going to be the crown jewel of UTHR’s products, Tyvaso DPI. This is a big deal and is what is driving MNKD share price. MC is not likely to bungle this because he is not in charge. Martine is, and she knows how to run a company and knows how to sell a drug. UTHR is rated a strong buy or buy by most analysts covering it. MNKD can succeed despite MC’s utter failure with Afrezza. |
|
|
|
Post by barnstormer on May 13, 2021 9:23:53 GMT -5
That's what everyone thought about Afrezza. The stock would fly. Then reality set in and inhalable insulin didn't take off. Even Martine stated on an investor's call that there was no guarantee PAH patients would convert to Tyvaso. So I hope (not a good investment strategy) you're right and the stock triples. But that's what we hoped for with Afrezza. Hello Barnstormer, I read every word you have written and consider them. Consider the promise of COPD. COPD with Martine leading the charge. Perhaps that is what is being priced in. As far as partners, I am hoping CEO's look at what Martine is doing and wonder why she is having all the fun. Just talkin. Hi Peppy. Thanks for your input. I am not selling my shares yet, even though they go from red to green back to red based on my average and MNKDs volatility. I would love to see share price triple, but counting on Martine to save MNKD investors is a sad reflection on Mike and his bandits. Mike's inability to make Afrezza a success is a bad reflection on TS as a platform and hinders it IMHO from being considered by other formulations, thus the lack of other partners and growth. |
|
